首页 | 本学科首页   官方微博 | 高级检索  
文章检索
  按 检索   检索词:      
出版年份:   被引次数:   他引次数: 提示:输入*表示无穷大
  收费全文   151篇
  免费   4篇
  国内免费   12篇
耳鼻咽喉   1篇
儿科学   10篇
妇产科学   2篇
基础医学   15篇
口腔科学   2篇
临床医学   19篇
内科学   18篇
皮肤病学   1篇
神经病学   2篇
特种医学   51篇
外科学   9篇
综合类   17篇
预防医学   7篇
眼科学   2篇
药学   7篇
肿瘤学   4篇
  2021年   2篇
  2018年   2篇
  2017年   1篇
  2016年   1篇
  2015年   3篇
  2014年   1篇
  2013年   6篇
  2012年   6篇
  2010年   4篇
  2009年   4篇
  2008年   1篇
  2007年   7篇
  2006年   9篇
  2005年   12篇
  2004年   1篇
  2003年   1篇
  2002年   1篇
  2001年   4篇
  1998年   8篇
  1997年   6篇
  1996年   8篇
  1995年   5篇
  1994年   4篇
  1993年   9篇
  1992年   4篇
  1989年   5篇
  1988年   3篇
  1987年   3篇
  1986年   1篇
  1985年   6篇
  1984年   3篇
  1983年   4篇
  1982年   2篇
  1981年   3篇
  1980年   4篇
  1979年   3篇
  1978年   5篇
  1977年   3篇
  1976年   1篇
  1975年   2篇
  1971年   2篇
  1964年   2篇
  1963年   1篇
  1962年   1篇
  1961年   3篇
排序方式: 共有167条查询结果,搜索用时 0 毫秒
161.
Three patients with clinically suspected pseudoaneurysm as a complication of femoral puncture were referred for ultrasound (US) evaluation with both conventional duplex Doppler US and color Doppler imaging. Pseudoaneurysm (n = 2) and simple hematoma (n = 2) were depicted with both Doppler systems, and a separate pseudoaneurysm and a hematoma were found in one patient. These diagnoses were confirmed surgically. Distinctive Doppler spectral waveforms and color Doppler findings enabled confident diagnoses. Color Doppler imaging allowed faster detection of intraaneurysmal flow, and the track between the injured artery and the pseudoaneurysm was identified only with color Doppler imaging. Duplex Doppler US with color Doppler imaging allows for the rapid, unequivocal diagnosis of pseudoaneurysm, thus enabling prompt treatment without the need for invasive diagnostic modalities.  相似文献   
162.
此随机、双盲研究旨在比较地特胰岛素与甘精胰岛素和NPH在1型糖尿病患者中降糖疗效受试者个体内的变异性。54名受试者(32名男性和22名女性,年龄38±10岁,BMI24±2kg/m^2,  相似文献   
163.
Objective:  Periodontal disease is an inflammatory disorder with widespread morbidities involving both oral and systemic health. The primary goal of periodontal treatment is the regeneration of the lost or diseased periodontium. In this study, we retrospectively examined feasibility and safety of reconstructing the periodontal intrabony defects with autologous periodontal ligament progenitor (PDLP) implantation in three patients.
Materials and methods:  In this retrospective pilot study, we treated 16 teeth with at least one deep intrabony defect of probing depth (PD) ≥ 6 mm with PDLP transplantation and evaluated clinical outcome measures in terms of probing depth, gingival recession and attachment gain for a duration of 32–72 months. Furthermore, we compare PDLPs with standard PDL stem cells (PDLSCs) and confirmed that PDLPs possessed progenitor characters.
Results:  Clinical examination indicated that transplantation of PDLPs may provide therapeutic benefit for the periodontal defects. All treated patients showed no adverse effects during the entire course of follow up. We also found that PDLPs were analogous to PDLSCs in terms of high proliferation, expression of mesenchymal surface molecules, multipotent differentiation, and in vivo tissue regain. However, PDLPs failed to express scleraxis, a marker of tendon, as seen in PDLSCs.
Conclusions:  This study demonstrated clinical and experimental evidences supporting a potential efficacy and safety of utilizing autologous PDL cells in the treatment of human periodontitis.  相似文献   
164.

Background and purpose:

The histamine H4 receptor is widely expressed in cells of immune origin and has been shown to play a role in a variety of inflammatory processes mediated by histamine. In this report, we describe the in vitro and in vivo anti-inflammatory properties of a potent histamine H4 receptor antagonist, A-940894 (4-piperazin-1-yl-6,7-dihydro-5H-benzo[6,7]cyclohepta[1,2-d]pyrimidin-2-ylamine).

Experimental approach:

We have analysed the pharmacological profile of A-940894 at mouse native, rat recombinant and human recombinant and native, histamine H4 receptors by radioligand binding, calcium mobilization, mast cell shape change, eosinophil chemotaxis assays and in the mouse model of zymosan-induced peritonitis.

Key results:

A-940894 potently binds to both human and rat histamine H4 receptors and exhibits considerably lower affinity for the human histamine H1, H2 or H3 receptors. It potently blocked histamine-evoked calcium mobilization in the fluorometric imaging plate reader assays and inhibited histamine-induced shape change of mouse bone marrow-derived mast cells and chemotaxis of human eosinophils in vitro. In a mouse mast cell-dependent model of zymosan-induced peritonitis, A-940894 significantly blocked neutrophil influx and reduced intraperitoneal prostaglandin D2 levels. Finally, A-940894 has good pharmacokinetic properties, including half-life and oral bioavailability in rats and mice.

Conclusions and Implications:

These data suggest that A-940894 is a potent and selective histamine H4 receptor antagonist with pharmacokinetic properties suitable for long-term in vivo testing and could serve as a useful tool for the further characterization of histamine H4 receptor pharmacology.  相似文献   
165.
Oral Diseases (2010) 16 , 709–716 Although advances in surgical techniques and bone grafting have significantly improved the functional and cosmetic restoration of craniofacial structures lost because of trauma or disease, there are still significant limitations in our ability to regenerate these tissues. The regeneration of oral and craniofacial tissues presents a formidable challenge that requires synthesis of basic science, clinical science, and engineering technology. Tissue engineering is an interdisciplinary field of study that addresses this challenge by applying the principles of engineering to biology and medicine toward the development of biological substitutes that restore, maintain, and improve normal function. This review will explore the impact of biomaterials design, stem cell biology and gene therapy on craniofacial tissue engineering.  相似文献   
166.
167.
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号